ras Oncogene – Talk Bio

BridgeBio Oncology Therapeutics: Recent News Overview (November 2025)

2 weeks ago talkbio0Tagged AACR-NCI-EORTC, BridgeBio Oncology Therapeutics, clinical-stage biopharma, de-SPAC transaction, financial results, financing characteristics, Helix Acquisition Corp II, PI3Kδ, Piperine Extract (Standardized), ras Oncogene, third quarter 2025

BridgeBio Oncology Therapeutics; Helix Acquisition Corp II; de-SPAC transaction; PIPE financing; RAS and PI3Kα; clinical-stage biopharma; AACR-NCI-EORTC Conference; third quarter 2025 financial results

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

9 months ago talkbio0Tagged Biochemical Pathway, BridgeBio, cancer pipeline, Helix (Snails), inhibitors, K-ras Oncogene, KRAS, Merger, Neoplasms, PI3 K pathway, ras Oncogene, SPAC

BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway

Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805

1 year ago talkbio0Tagged cellular targeting, Clinical Trials, inhibitors, Pancreatic carcinoma, ras Oncogene, Revolution Medicines, RMC-6236, RMC-9805

Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials